Quantitative characterization of tumor cell-free DNA shortening

BMC Genomics

Table 1 Clinical demographics of the 134/144 bp dominant and the 166 bp dominant cfDNA samples

		134/144 bp Dominant (n = 35)	166 bp Dominant (n = 35)	p-value
Gender	Male	28	21	0.1165^a
Gender	Female	7	14	0.1165^a
Age	> = 60	18	26	0.0824^a
	< 60	17	9	0.0824^a
	Median	60	65	0.0046^b
Primary tumor site	Lung	19	22	0.0644^c
	Gastrointestinal tract	5	10
	Liver	4	0
	Other	7	3
Stage	III	3	1	0.6859^c
	IV	21	21
	Unknown	11	13
Metastasis	Yes	20	18	0.8106^a
Metastasis	No	15	17	0.8106^a
Surgery within 30 days	Yes	0	1	1.0000^a
Surgery within 30 days	No	35	34	1.0000^a
Radiation therapy within 30 days	Yes	3	1	0.6139^a
Radiation therapy within 30 days	No	32	34	0.6139^a
Chemotherapy within 30 days	Yes	4	8	0.3420^a
Chemotherapy within 30 days	No	31	27	0.3420^a
Targeted therapy within 30 days	Yes	4	8	0.3420^a
Targeted therapy within 30 days	No	31	27	0.3420^a

ISSN: 1471-2164